Evidence Supporting the Hypothesis That Inflammation-Induced Vasospasm Is Involved in the Pathogenesis of Acquired Sensorineural Hearing Loss
Table 2
Evidence for effectiveness of magnesium in prevention of noise-induced SNHL from randomised controlled trials in humans.
Design
Number of participants
Age of participants
Intervention
Outcome
Critical appraisal
Reference
Placebo-controlled double blind
28 participants in total, number per group unknown
22 to 75 years of age, mean 53 years
6.7 mmol of magnesium aspartate orally once a day
Improvement of sudden SNHL excluding noise, mumps, Meniere’s disease, and traumatic SNHL: more patients with improved hearing and a greater improvement in those with SSNHL were noted in the magnesium treated group across all frequencies assessed
The investigation did not report method of randomisation, number randomised into each group, and number of patients with improved hearing for each frequency
215 participants, 105 in the magnesium group, and 110 in the placebo group
18-year-old men
6.7 mmol of magnesium aspartate orally once a day
There was a noise-induced pure tone audiometry threshold shift (>25 dB at 3 to 8 kHz) in 11.2% (both ears) of the magnesium group and 21.5% in the left ear and 28.5% in the right ear in the placebo group
The method of randomisation was unclear, and the duration of prophylactic treatment and timing of sampling were not specified